Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation

British Journal of Haematology

Volumn 157, Issue 2, 2012, Pages 220-229

  Ringdén, Olle ^a   Labopin, Myriam ^b   Gorin, Norbert Claude ^b   Volin, Liisa ^c   Torelli, Giovanni F ^d   Attal, Michel ^e   Jouet, Jean P ^f   Milpied, Noel ^g   Socié, Gerard ^h   Cordonnier, Catherine ⁱ   Michallet, Mauricette ^j   Atienza, Arturo I ^k   Hermine, Olivier ^l   Mohty, Mohamad ^m  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HÔPITAL SAINT ANTOINE   (France)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CHU PURPAN   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Allogeneic haematopoietic stem cell transplantation; Chemotherapy; Graft versus host disease; Granulocyte colony stimulating factor; Total body irradiation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT REJECTION; HAZARD RATIO; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SIBLING; THROMBOCYTE COUNT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859217738     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09034.x     Document Type: Article

References (31)

1. American Society of Clinical Oncology. (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. Journal of Clinical Oncology, 14, 1957-1960.
2. Appelbaum, F.R. (1995) Allogeneic marrow transplantation and the use of hematopoietic growth factors. Stem Cells, 13, 344-350.
3. Berger, C., Bertz, H., Schmoor, C., Behringer, D., Potthoff, K., Mertelsmann, R. & Finke, J. (1999) Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplantation, 23, 983-990.
4. Bishop, M.R., Tarantolo, S.R., Pavletic, Z.S., Lynch, J.C., Morris, M.E., Zacharias, D., Armitage, J.O. & Kessinger, A. (2000) Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. Journal of Clinical Oncology, 18, 2269-2272.
5. Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, Jr, F.R., Ringden, O. & Wagner, J.E. (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. Journal of Clinical Oncology, 22, 4872-4880.
6. Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94, 496-509.
7. Gisselbrecht, C., Prentice, H.G., Bacigalupo, A., Biron, P., Milpied, N., Rubie, H., Cunningham, D., Legros, M., Pico, J.L., Linch, D.C., Burnett, A.K., Scarffe, J.H., Siegert, W. & Yver, A. (1994) Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet, 343, 696-700.
8. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295-304.
9. Gooley, T.A., Leisenring, W., Crowley, J. & Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695-706.
10. Gupta, P., Tiley, C., Powles, R., Treleaven, J., Millar, J. & Catalano, J. (1992) No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 9, 491-493.
11. Hagglund, H., Ringden, O., Oman, S., Remberger, M., Carlens, S. & Mattsson, J. (1999) A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplantation, 24, 831-836.
12. Ho, V.T., Mirza, N.Q., Junco Dd, D., Okamura, T. & Przepiorka, D. (2003) The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplantation, 32, 771-775.
13. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E. & Bortin, M.M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-562.
14. Kawano, Y., Takaue, Y., Mimaya, J., Horikoshi, Y., Watanabe, T., Abe, T., Shimizu, Y., Matsushita, T., Kikuta, A., Watanabe, A., Iwai, A., Ito, E., Endo, M., Kodani, N., Ohta, S., Gushi, K., Azuma, H., Etoh, T., Okamoto, Y., Amano, K., Hattori, H., Eguchi, H. & Kuroda, Y. (1998) Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood, 92, 4040-4046.
15. Khoury, H.J., Loberiza, Jr, F.R., Ringden, O., Barrett, A.J., Bolwell, B.J., Cahn, J.Y., Champlin, R.E., Gale, R.P., Hale, G.A., Urbano-Ispizua, A., Martino, R., McCarthy, P.L., Tiberghien, P., Verdonck, L.F. & Horowitz, M.M. (2006) Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood, 107, 1712-1716.
16. Kobayashi, S., Imamura, M., Hashino, S., Noto, S., Mori, A., Tanaka, J., Naohara, T., Kasai, M. & Asaka, M. (1999) Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. Leukaemia & Lymphoma, 33, 559-566.
17. Mathias, C., Mick, R., Grupp, S., Duffy, K., Harris, F., Laport, G., Stadtmauer, E., Luger, S., Schuster, S., Wasik, M.A. & Porter, D.L. (2000) Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. Journal of Hematotherapy & Stem Cell Research, 9, 393-400.
18. Miyamoto, T., Akashi, K., Hayashi, S., Gondo, H., Murakawa, M., Tanimoto, K., Harada, M. & Niho, Y. (1996) Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplantation, 17, 185-190.
19. Morris, E.S., MacDonald, K.P., Kuns, R.D., Morris, H.M., Banovic, T., Don, A.L., Rowe, V., Wilson, Y.A., Raffelt, N.C., Engwerda, C.R., Burman, A.C., Markey, K.A., Godfrey, D.I., Smyth, M.J. & Hill, G.R. (2009) Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nature Medicine, 15, 436-441.
20. Powles, R., Smith, C., Milan, S., Treleaven, J., Millar, J., McElwain, T., Gordon-Smith, E., Milliken, S. & Tiley, C. (1990) Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet, 336, 1417-1420.
21. Remberger, M. & Ringden, O. (1995) Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation. Transplantation, 60, 1293-1299.
22. Remberger, M. & Sundberg, B. (2005) Granulocyte colony-stimulating factor affects serum levels of soluble interleukin-2 receptors after allogeneic stem cell transplantation. Haematologica, 90, 427-429.
23. Remberger, M., Naseh, N., Aschan, J., Barkholt, L., LeBlanc, K., Svennberg, P. & Ringden, O. (2003) G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplantation, 32, 217-223.
24. Ringden, O. & Deeg, H.J. (1996) Clinical spectrum of graft-versus-host disease. In: Graft vs Host Disease, 2nd edn (ed. by J.L.M. Ferrara, H.J. Deeg & S. Burakoff), pp. 525-559. Marcel Dekker Inc, New York.
25. Ringden, O., Labopin, M., Gorin, N.C., Le Blanc, K., Rocha, V., Gluckman, E., Reiffers, J., Arcese, W., Vossen, J.M., Jouet, J.P., Cordonnier, C. & Frassoni, F. (2004) Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 22, 416-423.
26. Ringden, O., Karlsson, H., Olsson, R., Omazic, B. & Uhlin, M. (2009) The allogeneic graft-versus-cancer effect. British Journal of Haematology, 147, 614-633.
27. Ringden, O., Hassan, Z., Karlsson, H., Olsson, R., Omazic, B., Mattsson, J. & Remberger, M. (2010) Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation, 90, 1022-1029.
28. Sloand, E.M., Kim, S., Maciejewski, J.P., Van Rhee, F., Chaudhuri, A., Barrett, J. & Young, N.S. (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood, 95, 2269-2274.
29. Sullivan, K.M., Shulman, H.M., Storb, R., Weiden, P.L., Witherspoon, R.P., McDonald, G.B., Schubert, M.M., Atkinson, K. & Thomas, E.D. (1981) Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood, 57, 267-276.
30. Volpi, I., Perruccio, K., Tosti, A., Capanni, M., Ruggeri, L., Posati, S., Aversa, F., Tabilio, A., Romani, L., Martelli, M.F. & Velardi, A. (2001) Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood, 97, 2514-2521.
31. Weiden, P.L., Sullivan, K.M., Flournoy, N., Storb, R. & Thomas, E.D. (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New England Journal of Medicine, 304, 1529-1533.